What Allist Pharmaceuticals does

Allist Pharmaceuticals (Shanghai Allist Pharmaceuticals Co., Ltd., 上海艾力斯医药科技股份有限公司) is a Shanghai-based, publicly listed (Shanghai STAR Market, ticker 688578) biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule targeted therapies for non-small cell lung cancer (NSCLC). Founded in March 2004 by Du Jinhao and Dr. Guo Jianhui (a tenured NIH scientist), the company pivoted entirely to oncology following Dr. Guo's passing in 2012 and listed on the STAR Market in December 2020 after raising over RMB 1B in 2019 A/A+ rounds. Allist's portfolio centers on three approved products: Furmonertinib (Iversa, 艾弗沙), a third-generation EGFR tyrosine kinase inhibitor featuring a proprietary trifluoroethoxypyridine structure that delivers best-in-class 20.8-month median PFS and superior brain penetration in first-line EGFR-mutated NSCLC; Glecirasib (Airuikai, 艾瑞凯), the only once-daily oral KRAS G12C inhibitor approved in China (May 2025) using an innovative drug co-crystal approach; and Pralsetinib (Pujiquhua, 普吉华), a RET inhibitor for which Allist holds exclusive mainland China commercial promotion rights from CStone Pharmaceuticals.

Allist's core technology platforms are drug molecular design and discovery, and drug design and optimization based on metabolism, anchored by Chief Chemistry Officer Luo Huibing (the 'father of Furmonertinib'). The pipeline is extended through in-licensing: ABK3376 (fourth-generation EGFR TKI targeting C797S) from Abbisko Therapeutics for up to $187.9M in milestones, and glecirasib plus SHP2 inhibitors from Jacobio Pharma. Overseas, Allist out-licensed furmonertinib to ArriVent Biopharma in June 2021 for $40M upfront plus milestones and royalties, with global Phase III trials underway in 21+ countries. All three commercialized products were included in China's 2025 National Reimbursement Drug List effective January 1, 2026.

The company generates revenue primarily through domestic hospital and DTP pharmacy sales of its three products, supplemented by licensing royalties from ArriVent. Allist operates a 950+ member commercial team covering all 31 Chinese provinces, with 1000+ hospital and 300+ DTP pharmacy access points. Manufacturing is conducted at Jiangsu Allist Biomedical (Qidong, 73,337 sqm, RMB 240M registered capital). FY2023 operating revenue reached RMB 2.018B with RMB 644M net profit, and the company has been profitable since 2021, demonstrating commercial viability for an oncology innovator in the China market.

Name

Allist Pharmaceuticals

Legal name

上海艾力斯医药科技股份有限公司 (Shanghai Allist Pharmaceuticals Co., Ltd.)

Website

https://allist.com.cn

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Allist Pharmaceuticals is a Shanghai-based, publicly listed (STAR Market 688578) biopharmaceutical company that discovers, develops, and commercializes small-molecule targeted therapies for non-small cell lung cancer, including third-generation EGFR TKI Furmonertinib, KRAS G12C inhibitor Glecirasib, and RET inhibitor Pralsetinib (China promotion rights), sold through a 950+ person team covering all 31 Chinese provinces.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Targeted oncology drugs
• EGFR inhibitors
• KRAS G12C inhibitors
• RET fusion inhibitors
• Lung cancer therapeutics

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

1. Product Sales (Domestic China): Allist generates revenue primarily through domestic Chinese sales of its approved drugs: Furmonertinib (Iversa/Aifusha), Glecirasib (Airuikai/Airuikai), and promoted product Pralsetinib (Pujiquhua). Products are sold through hospital prescriptions and DTP pharmacies across China. All three products were included in the 2025 National Reimbursement Drug List.
2. Licensing Royalties (Overseas): Allist receives upfront payments, registration and sales milestone payments, and royalties on overseas sales from its partnership with ArriVent Biopharma for Furmonertinib's global development and commercialization outside Greater China. $40 million upfront received in June 2021.
3. Exclusive Commercialization Rights: Allist holds exclusive commercial promotion rights in mainland China for Pralsetinib (Gavreto) from CStone Pharmaceuticals (Jijushipu), generating revenue through sales of the product in the Chinese market.
4. License-In Revenue: Allist in-licensed KRAS G12C inhibitor Glecirasib and SHP2 inhibitors from Jacobtech Pharma (加科思药业) for China development and commercialization, with milestone payments and royalties going to Jacobtech. Glecirasib approved May 2025 as Airuikai.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Allist Pharmaceuticals discovers, develops, manufactures, and commercializes innovative targeted small-molecule oncology drugs in China, focused on non-small cell lung cancer (NSCLC). Its commercial portfolio centers on three products: Furmonertinib (艾弗沙/Ivesa), a third-generation EGFR tyrosine kinase inhibitor (TKI); Glecirasib (艾瑞凯/Airuikai), a KRAS G12C inhibitor; and Pralsetinib (普吉华/Pujiquhua), a RET inhibitor marketed under exclusive mainland China promotion rights. The company runs an in-house R&D center in Shanghai and a manufacturing base in Jiangsu, and uses a 950+ commercial team to sell through hospitals and DTP pharmacies nationally.

Product overview

Allist Pharmaceuticals is an innovative biopharmaceutical company focused on oncology drug discovery, development, manufacturing, and commercialization. The company's product portfolio centers on targeted therapies for lung cancer, comprising three key commercialized products: (1) 艾弗沙® (Furmonertinib), a third-generation EGFR-TKI and the core product approved for EGFR-mutated NSCLC first-line and second-line treatment; (2) 艾瑞凯® (Glecirasib), a KRAS G12C inhibitor approved in 2025 for KRAS G12C-mutated advanced NSCLC; and (3) 普吉华® (Pralsetinib), a RET inhibitor for which Allist holds exclusive China mainland promotion rights. The company also maintains a pipeline of assets in development including next-generation EGFR inhibitors, SHP2 inhibitors, and combination therapies.

Differentiator

Problem solved

Functional benefit

Brands

• 艾弗沙 (IVESA): Brand name for furmonertinib mesylate tablets (甲磺酸伏美替尼片), a third-generation EGFR-TKI for NSCLC treatment. Approved in China for EGFR-sensitive mutations first-line and second-line treatment, EGFR exon 20 insertion mutations, and EGFR PACC mutations.
• 艾瑞凯 (Airuikai)
• 普吉华 (Gavreto)

Products and services

• 艾弗沙 (Furmonertinib / Ivesa) - 甲磺酸伏美替尼片 A third-generation EGFR tyrosine kinase inhibitor (TKI) with independent Chinese intellectual property rights, characterized by dual activity, dual brain-penetration, and well-managed safety. Approved in China for first-line and second-line treatment of EGFR-mutated locally advanced or metastatic NSCLC (sensitive mutations, T790M), EGFR exon 20 insertion mutations, and EGFR PACC mutations. Used by oncologists treating NSCLC patients in hospital and DTP pharmacy settings.
• 艾瑞凯 (Glecirasib / Airuikai) - 枸橼酸戈来雷塞片 A once-daily oral KRAS G12C inhibitor using an innovative drug co-crystal approach, approved in China in May 2025 for treatment of adult patients with KRAS G12C-mutated advanced NSCLC who have previously received at least one line of systemic therapy. It is the only once-daily oral KRAS G12C inhibitor approved in China, with ongoing development in combination with SHP2 inhibitor AST24082 and in colorectal/pancreatic cancer. Licensed in from Jacobio Pharma.
• 普吉华 (Pralsetinib / Pujiquhua / Gavreto) - 普拉替尼胶囊 An oral, once-daily, highly selective RET receptor tyrosine kinase inhibitor marketed in mainland China by Allist under exclusive commercial promotion rights sourced from CStone Pharmaceuticals (originating drug from Genentech/Blueprint Medicines). Approved in China for three indications: RET gene fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer.

Quantifiable outcome

• Furmonertinib achieved 20.8-month median PFS vs 11.1 months for gefitinib (HR 0.44), representing a 56% reduction in risk of disease progression or death in first-line EGFR-mutated NSCLC (FURLONG Phase III study, n=358).
• +5 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core, minor and major.

• Jacobtech Pharma (加科思药业, Stock: 1167.HK)coreOEM/ Whitelabel/ Licensing Partner · 30 August 2024Allist obtained exclusive development and commercialization rights in China (mainland, Hong Kong, Macau, Taiwan) for KRAS G12C inhibitor glecirasib and SHP2 inhibitors AST24082 and JAB-3312. Glecirasib approved May 2025 (Airuikai) for KRAS G12C-mutated NSCLC. SHP2 inhibitor AST24082 combined with glecirasib showing 71% ORR and 12.2-month median PFS in first-line NSCLC. Pancreatic cancer indication received orphan drug designation in US and Europe.
• Abbisko Therapeutics Co., Ltd.coreStrategic or Co-development Partner · 1 March 2023Abbisko granted Allist exclusive rights for ABK3376 (next-generation EGFR TKI targeting C797S mutations) in Greater China with option to expand globally. Allist paid up to $187.9 million USD for upfront, development, and commercial milestones plus tiered royalties. ABK3376 is a highly selective, brain-penetrating fourth-generation EGFR TKI in preclinical stage. Additionally, the companies are jointly conducting a Phase 2 clinical study of oral PD-L1 small molecule ABSK043 in combination with furmonertinib for advanced NSCLC (IND filed 2024).
• Shanghai Chest Hospital (Prof. Baohui Han)minorStrategic or Co-development Partner · 1 January 2023Prof. Baohui Han from Shanghai Chest Hospital presented furmonertinib FAVOUR study data (EGFR exon 20 insertion mutations) at 2023 WCLC. This collaboration generated key clinical data supporting furmonertinib's EGFR exon 20 insertion mutation indication and FDA Breakthrough Therapy Designation.
• Fudan University (School of Pharmacy)minorStrategic or Co-development Partner · 28 July 2021Allist signed a technology transfer agreement with Fudan University for PGAM1 (Phosphoglycerate Mutase 1) Inhibitor KH3. Allist received all research results, domestic and foreign patent rights, and all rights for domestic and foreign development, registration, and sales. KH3 is a first-in-class allosteric inhibitor targeting pancreatic cancer and other tumors with high PGAM1 expression.
• ArriVent Biopharma, Inc.coreOEM/ Whitelabel/ Licensing Partner · 30 June 2021Allist granted ArriVent exclusive overseas license (outside mainland China, Hong Kong, Macau, Taiwan) for Furmonertinib's global development and commercialization. Allist received $40 million upfront and is eligible for registration and sales milestone payments plus royalties on overseas sales. Global multi-center Phase III trials (FURVENT/FURMO-004) for EGFR exon 20 insertion mutation indication are underway in over 21 countries including China, US, UK, France, Japan, and South Korea. ArriVent is also developing Firmonertinib (furmonertinib's overseas name) with Phase 3 readout expected mid-2026. This is Allist's flagship international partnership.
• Cancer Hospital Chinese Academy of Medical Sciences (Principal Investigator: Prof. Yuankai Shi)coreStrategic or Co-development Partner · 11 January 2021Allist collaborated with Prof. Yuankai Shi's team at the Cancer Hospital Chinese Academy of Medical Sciences for the FURLONG Phase III clinical trial (furmonertinib vs gefitinib in first-line EGFR-mutated NSCLC) and the pivotal Phase IIb registration study. FURLONG results published in The Lancet Respiratory Medicine established furmonertinib as the first third-generation EGFR TKI to achieve >20-month PFS in first-line treatment.
• CStone Pharmaceuticals (基石药业, Stock: 2616.HK)majorChannel Partner/ Reseller/ Distributor · 1 January 2021Allist holds exclusive commercial promotion rights in mainland China for pralsetinib (Gavreto/Pujiquhua), a RET inhibitor developed by CStone Pharmaceuticals. Pralsetinib has three approved indications in China: RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. All three indications were included in the 2025 National Reimbursement Drug List.
• OCTIMET Oncology (Belgium)minorStrategic or Co-development Partner · 1 January 2020Allist partnered with OCTIMET Oncology for joint development of combination therapy using furmonertinib with OCTIMET's proprietary EGFR TKI (osimertinib metabolite). The collaboration aimed to explore synergistic treatment approaches for NSCLC.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• BeiGene: China-founded and listed global oncology biotech with a deep targeted-therapy and immuno-oncology portfolio; directly comparable as a China-based publicly listed innovator with NRDL access and global Phase III ambitions overlapping NSCLC.
• Hutchmed (China): China-headquartered oncology-focused biopharma commercializing innovative targeted therapies (e.g., surufatinib, savolitinib); comparable business model of NRDL-driven domestic launches plus ex-China partnering, and overlapping NSCLC focus.
• Innovent Biologics: Chinese biotech with multiple NRDL-listed oncology biologics and small molecules; comparable as a publicly listed China oncology innovator with strong commercial scale and a pipeline overlapping NSCLC targeted therapy.
• Akeso: China-based oncology biologics innovator with multiple NRDL-included immuno-oncology assets; comparable as a China-listed targeted-therapy developer with strong commercial expansion and pipeline depth.
• Jacobio Pharmaceuticals: HK-listed (1167.HK) China oncology biotech and the originator of Glecirasib and SHP2 inhibitors that Allist in-licensed; direct comparable in KRAS/SHP2 mechanism, NSCLC focus, and NRDL/China commercialization model.
• CStone Pharmaceuticals: HK-listed (2616.HK) China oncology biotech that developed Pralsetinib (Gavreto) and granted Allist exclusive China promotion rights; directly comparable targeted-therapy innovator with overlapping NRDL strategy.
• Abbisko Therapeutics: China oncology biotech developing next-generation EGFR TKIs (ABK3376, licensed to Allist) and PD-L1 small molecules; directly comparable as a China precision-oncology peer in the EGFR resistance space.

Broad incumbents

• AstraZeneca: Global incumbent in EGFR TKIs via Tagrisso (osimertinib), the dominant third-generation competitor to Furmonertinib; broad incumbent in the same oncology space where Allist competes for share.
• Jiangsu Hengrui Pharmaceuticals: China's largest domestic innovative pharma with broad oncology, anesthesia and cardiometabolic portfolios; broad incumbent with overlapping NRDL-driven oncology commercial footprint and EGFR TKI competitors (e.g., pyrotinib, camrelizumab combinations).

Others

• ArriVent BioPharma: US clinical-stage biotech that exclusively licensed Furmonertinib overseas from Allist and is running the global FURVENT Phase III; ecosystem partner/related party rather than competitor, but a key strategic peer in the EGFR exon 20 insertion global development race.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/allist-pharmaceuticals-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allist Pharmaceuticals